Abstract:Abstract Background: Pediatric brain tumors are associated with the highest rates of morbidity and mortality of all childhood cancers. Diffuse midline gliomas (DMGs) are universally fatal pediatric tumors with a median survival of less than one year. DMGs are thought to arise from stalled developmental programs in the context of histone mutations (H3 K27M) which are thought to be a critical initiating event. However, these histone mutations alone are insufficient for gliomagenesis and cooperate with other alterations, including mutations in the TP53 pathway (TP53, PPM1D), growth factor receptor pathway activation (PDGFRA, EGFR, PIK3CA), and MYC amplifications (MYC, MYC-N) to induce tumor formation. There is a high degree of genetic heterogeneity amongst DMGs, and other alterations are also critical to DMG pathogenesis. This work is focused on Forkhead Box R2 (FOXR2), a forkhead family TF that we have found to be aberrantly expressed in many cancers, including DMGs. Expression of FOXR2 is sufficient to enhance glioma formation, and we have shown that regulation of FOXR2 occurs through a previously unrecognized epigenetic mechanism. Expression of FOXR2 is regulated by novel promoters, and we have demonstrated that these promoters are necessary for FOXR2 expression in several cancer lineages using CRISPR interference technology, including DMGs, melanoma, neuroblastoma, and non-small cell lung cancers. Methods: We applied an integrative approach using transcriptomics, epigenetics, proteomics, in vitro cancer models, and in vivo mouse models to systematically evaluate how FOXR2 mediates gliomagenesis. Results: We have found that FOXR2 is activated across multiple cancer lineages, including DMGs. FOXR2 is required for proliferation in vitro, and it is sufficient to enhance gliomagenesis using an in utero electroporation in vivo mouse model. FOXR2 enhances MYC protein stability, even in the presence of cycloheximide. However, FOXR2 also exerts its oncogenic effects through MYC independent functions. FOXR2 is highly enriched at E26-transformation (ETS) motifs and specifically activates ETS transcriptional gene sets. To determine protein-protein interactions of FOXR2, we have performed immunoprecipitation and mass spectrometry to identify FOXR2 protein interactors. Moreover, we have performed both proteomic and phospho-proteomic analyses of FOXR2-expressing human neural stem cells. These proteomic studies have allowed us to identify proteins and phospho-sites that are highly enriched in FOXR2-expressing cells, and that could be potential therapeutic targets in FOXR2-expressing cancers. Conclusion: Taken together, this study elucidates how FOXR2 protein interactors mediate oncogenesis in FOXR2-expressing diffuse midline gliomas. These studies proposed here have broad applicability across a range of cancers as FOXR2 is aberrantly expressed in 8% of all cancers. Citation Format: Jessica W. Tsai, Marissa Coppola, Phonepasong Arounleut, Jared B. Collins, Patrick Hart, Hasmik Keshishian, David T. Jones, Pratiti Bandopadhayay, Timothy N. Phoenix. Delineating mediators of oncogenesis in FOXR2-expressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2854.

Tumorigenic effects of TLX overexpression in HEK 293T cells

The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche.

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma

Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors

Nuclear orphan receptor TLX affects gene expression, proliferation and cell apoptosis in beta cells.

Orphan Nuclear Receptor TLX Contributes to Androgen Insensitivity in Castration-Resistant Prostate Cancer Via Its Repression of Androgen Receptor Transcription.

Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma

Impaired Generation of Mature Neurons Due to Extended Expression of Tlx by Repressing Sox2 Transcriptional Activity

Orphan Nuclear Receptor TLX Regulates Astrogenesis by Modulating BMP Signaling

Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.

Promising Long Noncoding RNA DLX6-AS1 in Malignant Tumors

The nuclear receptor NR2E1/TLX controls senescence

TBL1X: At the crossroads of transcriptional and posttranscriptional regulation

Abstract B47: Overexpression of TLX3 or HOXA9 in association mutant IL7Rα are sufficient to generate T-ALL in vivo

Abstract 2854: Delineating mediators of oncogenesis in FOXR2 -expressing cancers

FOXR2 targets LHX6+/DLX+ neural lineages to drive CNS neuroblastoma

Retracted: Overexpression HERG K+ Channel Gene Mediates Cell‐growth Signals on Activation of Oncoproteins SP1 and NF‐κB and Inactivation of Tumor Suppressor Nkx3.1

Overexpression of Htlx3 in Association with Mutant IL7Rα is Sufficient to Generate T-ALL in Vivo and to Transform Thymocytes in Vitro

Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target

EPEN-31. Developmental and Oncogenic Transcription Factor Circuits as Dependencies in Ependymoma